Current Neurology and Neuroscience Reports

, Volume 5, Issue 1, pp 1–3

Antiplatelet medications in the secondary prevention of ischemic stroke

  • James D. Fleck
Invited Commentary

DOI: 10.1007/s11910-005-0015-2

Cite this article as:
Fleck, J.D. Curr Neurol Neurosci Rep (2005) 5: 1. doi:10.1007/s11910-005-0015-2

Conclusions

It is difficult to make general statements regarding choices in the medical management of patients with IS given its multiple mechanisms and individual patient variations. It is exceedingly important to manage all vascular risk factors in each patient, especially hypertension. Managing risk factors is as important as, or perhaps more important than, deciding on a prevention medication. Based on the previous discussion, I present my recommendations for antiplatelet secondary prevention of noncardioembolic IS.

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • James D. Fleck
    • 1
  1. 1.Department of NeurologyIndiana University School of MedicineIndianapolisUSA